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Notch receptor-mediated intracellular events represent an ancient cell signaling system, and alterations in Notch
expression are associated with various malignancies in which Notch may function as an oncogene or less com-
monly as a tumor suppressor. Notch signaling regulates cell fate decisions in the epidermis, including inﬂuencing
stem cell dynamics and growth/differentiation control of cells in skin. Because of increasing evidence that the
Notch signaling network is deregulated in human malignancies, Notch receptors have become attractive targets for
selective killing of malignant cells. Compared with proliferating normal human melanocytes, melanoma cell lines
are characterized by markedly enhanced levels of activated Notch-1 receptor. By using a small molecule gamma-
secretase inhibitor (GSI) consisting of a tripeptide aldehyde, N-benzyloxycarbonyl-Leu-Leu-Nle-CHO, which can
block processing and activation of all four different Notch receptors, we identiﬁed a specific apoptotic vulnerability
in melanoma cells. GSI triggers apoptosis in melanoma cells, but only G2/M growth arrest in melanocytes without
subsequent cell death. Moreover, GSI treatment induced a pro-apoptotic BH3-only protein, NOXA, in melanoma
cells but not in normal melanocytes. The use of GSI to induce NOXA induction overcomes the apoptotic resistance
of melanoma cells, which commonly express numerous cell survival proteins such as Mcl-1, Bcl-2, and survivin.
Taken together, these results highlight the concept of synthetic lethality in which exposure to GSI, in combination
with melanoma cells overexpressing activated Notch receptors, has lethal consequences, producing selective
killing of melanoma cells, while sparing normal melanocytes. By identifying signaling pathways that contribute to
the transformation of melanoma cells (e.g. Notch signaling), and anti-cancer agents that achieve tumor selectivity
(e.g., GSI-induced NOXA), this experimental approach provides a useful framework for future therapeutic strategies
in cutaneous oncology.
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The Notch signaling pathway plays a key role in cell fate
decisions during development, and also regulates cell-to-
cell interactions involving stem cell behavior, cell prolifera-
tion, differentiation, and death (Artavanis-Tsakonas et al,
1999). Notch was originally described by Thomas Hunt
Morgan in 1917 because Drosophila-bearing mutations in
Notch had a distinctive phenotype in which the structure of
the wing blades was irregular in shape (Morgan, 1917). Dr
Morgan received the 1933 Nobel Prize for his discoveries
concerning the role played by the chromosome in heredity.
Note how, compared with the smooth edge of normal
wings, hemizygous Notch deficiency imparts a serrated-like
appearance to the edge of the wing (Fig 1A). The actual
gene responsible for producing the distinctive phenotype
was cloned in 1985, and it was recognized that this se-
quence encoded a cell surface receptor (Wharton et al,
1985). Focusing on Notch by investigative skin biologists is
not a coincidence, as homozygous Notch deficiency (Notch
null genotype) characteristically causes a ‘‘neurogenic phe-
notype’’ in which the number of neurons in Drosophila was
increased secondary to a decrease in epidermal cells. This
is due to unrestrained differentiation of neuroectodermal cells
toward the neural phenotype (Artavanis-Tsakonas et al, 1999).
Thus, Notch signaling has continued to attract interest by cu-
taneous biologists since it first received notoriety in 1937, when
Poulson initially described this neurogenic cell fate switch in-
volving Drosophila’s ectodermal cuticle (Poulson, 1937).
Besides its role as a highly evolutionarily conserved
pathway regulating epithelial development, Notch signaling
has also been implicated beyond the epidermis to include
hair follicles and feathers (Kopan and Weintraub, 1993; Po-
well et al, 1998; Viallet et al, 1998). In mammals, the Notch
family consists of four different Notch receptors and several
Notch ligands (Lai, 2004). The Notch receptors are desig-
nated as Notch-1 through Notch-4, and the different ligands
include Jagged-1, Jagged-2, and Delta-like (DLL1, DLL3,
DLL4—see Fig 1B). The four known Notch receptors differ
by the number of epidermal growth factor-like (EGF-like)
repeats in the extracellular domain, as well as by the length
of the intracellular domain. The cell fates regulated by Notch
signaling include renewal of stem cells, and control of pro-
liferation, differentiation, and apoptosis (Fig 1B).Abbreviation: GSI, gamma-secretase inhibitor
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Figure 1C presents an overview of Notch signaling with a
simplified portrayal of intracellular biochemical events that
participate in Notch signaling (Hansson et al, 2004). The
affinity of Notch ligands for their cognate receptors is mod-
ulated by glycosylation and fucosylation of the extracellular
subunits (Nickoloff et al, 2003). Regulated proteolysis plays
a major role in Notch signaling. Notch receptors are pro-
duced as large single-chain precursors, which are cleaved
by serine proteases related to furin in the trans-Golgi to
generate calcium-stabilized heterodimeric receptors con-
sisting of an extracellular subunit and a trans-membrane
subunit. Once a cell expressing a Notch receptor is stim-
ulated by an adjacent cell via a Notch ligand on the cell
surface, the extracellular subunit is trans-endocytosed in
the ligand-expressing cell. The remaining transmembrane
subunit undergoes two consecutive enzymatically mediated
cleavages. The first activating cleavage event is mediated
by a metalloprotease-dependent TNF-a converting enzyme
(TACE) belonging to the disintegrin and metalloprotease
family (Mumm et al, 2000) that cleaves the extracellular
portion of the transmembrane subunit (Brou et al, 2000).
This step is rapidly followed by a second cleavage in the
transmembrane domain requiring a g-secretase/presenilin-1
complex (De Strooper et al, 1999; Okochi et al, 2002) to
generate an intracellular truncated version of the receptor
designated as NIC (Fig 1). Very recently, it was discovered
that g-secretase cleavage requires and is preceded by
mono-ubiquitination and endocytosis (Gupta-Rossi et al,
2004). Thus, the rate of cleavage of Notch-1 is finely mod-
ulated by multiple post-translational modifications and cel-
lular compartmentalization events.
The truncated or intracellular form of the Notch-1 recep-
tor (e.g., NIC-1) can then translocate to the nucleus, where it
forms a multimeric complex with a highly conserved tran-
scription factor (CBF1), and other transcriptional co-activa-
tors that influence the intensity and duration of Notch
signals (Jarriault et al, 1995; Lai, 2002). CBF-1 exists as a
repressor in the absence of Notch-1, forming a complex
with adaptor protein SKIP and one or more co-repressors,
including SMRT (signaling mediator of retinoid and thyroid
receptor), N-CoR and/or CIR (Nickoloff et al, 2003), and
histone deacetylase 1 (HDAC1). Notch-1 dissociates the
co-repressors and HDAC1 from CBF-1, instead recruiting
co-activator MAML1 (Mastermind in Drosophila), and hi-
stone acetyltransferases P/CAF, GCN5, and/or p300. The
ultimate result is activation of transcription at promoters
containing CBF-1-responsive elements. Since many of the
genes regulated in this manner are themselves transcription
factors, this process can ultimately result in induction or
repression of numerous genes. Thus, the ultimate outcome
for Notch signaling is to either stimulate or repress various
target genes (Lai, 2004). Three of the most commonly stud-
ied target genes for Notch signaling include Hairy-Enhancer
of split (HES), and HES-related proteins (HERP/HEY) as well
as p21WAF1, although cross-talk between Notch and the
Stat3 signaling pathway has been demonstrated as well
(Maier and Gessler, 2000; Rangarajan et al, 2001b; Kawa-
mata et al, 2002; Kamakura et al, 2004).
In addition to this ‘‘classical’’ pathway of Notch signaling,
other pathways are beginning to emerge. The role of Notch-
associated protein Deltex remains poorly understood. Del-
tex, of which there are several mammalian isoforms, binds
to the ankyrin repeats of Notch and has been proposed to
act as a downstream Notch mediator involved in JNK in-
hibition, as a nuclear mediator of Notch signaling, and as a
feedback inhibitor of Notch signaling (Nickoloff et al, 2003).
More recently, convincing evidence has been presented
that Notch-1 acts as a kinase activation scaffold, forming a
complex with Src-family protein tyrosine kinase Lck and
phosphoinositide-3-kinase (PI3K). This process leads to
activation of the PI3K-AKT pathway (Sade et al, 2004) and
may be responsible for survival signals mediated by Notch
activation. There is considerable evidence of cross-talk be-
tween the Notch and NF-kB pathways, but the molecular
details remain unclear. Transcriptional induction of all five
NF-kB subunits (Cheng et al, 2001) as well as more rapid
Figure 1
Historical perspective and overview of
Notch signaling. (A) Phenotypic appear-
ance of Drosophila wings in normal, wild
type as well as in flies bearing hem-
izygous Notch mutation. Note the serrat-
ed, rather than smooth contour, on the
wing edges in the mutant fly wings as first
described by Thomas Morgan in 1917. (B)
Diverse roles for Notch signaling that in-
fluence various cell fate decisions includ-
ing four different Notch receptors and
multiple Notch ligands. (C) Simplified
overview of Notch signaling pathway, in
which the activation of the Notch receptor
in the plasma membrane results in regu-
lated proteolysis involving a g-secretase/
presenilin complex to generate a truncat-
ed intracellular form (e.g., NIC) that trans-
locates to the nucleus and functions as a
transcription factor to influence gene ex-
pression including HES and other targets
(see text for further explanation).
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activation of NF-kB (Nickoloff et al, 2002; Palaga et al, 2003;
Jang et al, 2004) have been described.
Given the multitude of cell fate-regulatory processes
modulated by Notch signaling and the number of cell fate
decisions and post-developmental influences that Notch
signaling mediates in a diverse array of cell types, it is not
surprising that Notch plays a complex role in pathophysi-
ology, and that multiple positive and negative regulatory
circuits tightly control the activity of Notch receptors. In the
next section, we review the role of Notch signaling in a
physiological context (i.e., epidermal keratinocyte differen-
tiation), as well as in pathology, with special emphasis on
deregulation of Notch signaling in various neoplastic con-
ditions (Axelson, 2004).
Notch Signaling as a Proto-Oncogene or
Tumor Suppressor
Over the past two decades, many processes have been
identified in which Notch signaling is operative in normal
cells to maintain tissue homeostasis. Furthermore, with re-
gard to tumorigenesis, Notch may play a role as either a
tumor suppressor or as an oncogene (Radtke and Raj,
2003). In this section, we briefly review the role of Notch
signaling in the differentiation of epidermal keratinocytes
(Fig 2A), as well as the evidence that persistent activation of
Notch signaling can produce malignancies such as human T
cell acute lymphoblastic leukemias (Fig 2B). In general,
Notch signaling tends to delay and restrict differentiation
pathways, thereby maintaining cells in an undifferentiated
state (Varnum-Finney et al, 1998). This influence on cell
fates contributes to stem cell renewal for several tissue sites
including the central nervous system, and the bone marrow
(Hansson et al, 2004).
An important exception to this general rule is the epi-
dermal keratinocyte, because we and others have clearly
demonstrated that activation of Notch signaling promotes
epidermal keratinocyte differentiation (Lowell et al, 2000;
Rangarajan et al, 2001b; Nickoloff et al, 2002). Character-
izing expression patterns for Notch-1 in human tissues has
revealed that in the skin, Notch-1 was expressed by hair
follicles, sebaceous glands, and sweat glands (Baldi et al,
2004). In the epidermis, Notch-1 appears to first become
apparent in the suprabasal layers corresponding to the cells
undergoing initial differentiation (Nickoloff et al, 2002). All
four Notch receptors are expressed in the epidermis, with
Notch-2 being more basal than Notch-1, and Notch-3 and -
4 being more superficial than Notch-1. Notch ligand Delta-1
is expressed in ‘‘epidermal stem cells’’ (Lowell et al, 2000),
and Jagged-1 is expressed throughout non-cornified layers
(Nickoloff et al, 2002). Expression of Notch receptors and
ligands abruptly disappears in cornified layers. Rangarajan
et al (2001b) showed that in murine keratinocytes, Notch-1
induces cell cycle arrest and early differentiation, whereas
inhibiting late differentiation. Using a submerged epidermal
Figure 2
Opposite roles of Notch-1 receptor signaling in keratinocytes as a tumor suppressor, or in T-ALL cells as a proto-oncogene. (A) As Notch-1
receptor activation triggers growth arrest and differentiation in normal epidermal keratinocytes, it can function as a tumor suppressor. Presumably
highly regulated interaction between Jagged-1-expressing keratinocytes can deliver a physiological stimulus induced by Notch-1 receptors to
trigger differentiation in healthy skin. (B) Either a chromosomal translocation producing enhanced levels of activated Notch-1 receptors, or point
mutations in the Notch-1 receptor that enhance g-secretase-mediated activation of Notch-1 receptors, generate sustained Notch signaling cul-
minating in tumorigenesis. (T cell acute lymphoblastic leukemia, T-ALL). Although a chromosomal translocation is rare, occurring in approximately
10% of patients with T-ALL, the point mutations are observed in over 50% of T-ALL patients (Weng et al, 2004).
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equivalent model system, we demonstrated that activation
of Notch signaling (very likely, all four Notch receptors in
sequence) is necessary and sufficient for triggering terminal
differentiation, including cornification (Nickoloff et al, 2002).
Thus, in the skin, Notch-1 signaling could function in
keratinocytes as a tumor suppressor because of its ability to
trigger induction of differentiation (Fig 2A). The precise roles
of the other three Notch receptors in epidermopoiesis re-
main unknown and are presently under investigation. Addi-
tional and more direct evidence that Notch-1 can function
as a tumor suppressor is derived from in vivo studies in
which the long-term consequences of Notch-1 deficiency
were characterized using a chemical carcinogenesis proto-
col (Nicolas et al, 2003). Using a tissue-specific, gene-tar-
geting approach, Notch-1 / mice were found to have
enhanced b-catenin signaling and increased frequency of
skin tumors resembling basal cell carcinoma and squamous
cell carcinoma. This is consistent with the anti-proliferative
role of Notch-1 in murine keratinocytes. Whether Notch-1 is
a bona-fide tumor suppressor in the epidermis, i.e., whether
functional inactivation of Notch-1 is required for BCC or
SCC progression in humans, is not clear. Selective loss of
Notch-1 in advanced cervical cancer and cervical cancer
cell lines had been reported (Talora et al, 2002), but others
(Lathion et al, 2003) have been unable to reproduce these
findings, and we (Weijzen et al, 2003) have shown that not
only is Notch-1 expressed in advanced cervical cancer cells
and clinical specimens, but it is necessary for survival of
cervical cancer cells through its anti-apoptotic activity.
Thus, it appears that the role of Notch-1 in keratinocytes
is not so simple (Kadesch, 2004), as one group has reported
that forced overexpression of activated Notch-1 can par-
ticipate with HPV oncoproteins E6 and E7 to transform pri-
mary human keratinocytes (Lathion et al, 2003), and there is
other evidence that Notch-1 inhibits apoptosis in immortal-
ized keratinocytes (Rangarajan et al, 2001b) and in cervical
cancer cells (Nair et al, 2003). The work of Lathion et al shed
some light on this apparent contradiction. These authors
showed that intracellular Notch-1 expressed from a very
strong (i.e., cytomegalovirus) promoter at very high levels
inhibits the expression of E6 and E7 HPV oncoproteins, as
reported by Talora et al. When expressed in more moderate
amounts from a Rous sarcoma virus promoter, however,
intracellular Notch did not inhibit E6 or E7 expression, and
transformed keratinocytes in cooperation with them. These
findings underscore two crucial characteristics of Notch
signaling, concentration dependence and context depend-
ence. The effects of exogenously overexpressed Notch re-
ceptors do not necessarily correspond to those of the
spontaneously expressed proteins. Additionally, the co-
presence of other oncogenic alterations (such as inactiva-
tion of retinoblastoma (Rb) and p53 by viral oncoproteins)
affects the outcome of Notch signaling. This context de-
pendence has relevance to the concept of synthetic lethality
in that it suggests possible molecular explanations for dif-
ferential sensitivity of neoplastic versus normal cells to
Notch inhibition. In this case, inactivation of Rb and p53
results in the disabling of the G1 restriction point, thus lim-
iting the effects of p21 induction by Notch-1, while
synergizing with the anti-apoptotic signals mediated by
Notch-1. It should be noted that with the possible exception
of T-cells, intracellular Notch-1 (and Notch-2) transforms
cells of several lineages in the co-presence of viral onco-
proteins that inactivate Rb and p53 (Capobianco et al, 1997;
Jeffries and Capobianco, 2000; Rangarajan et al, 2001b;
Bocchetta et al, 2003). It should be kept in mind that the end
result of Notch signaling is dictated by the cellular context,
and the signal strength and duration, which in turn are reg-
ulated by post-translational modifications and pathways
that influence receptor recycling and membrane availability
(Panin and Irvine, 1998). In the following paragraph, we
briefly review evidence linking excessive or sustained Notch
receptor activation to its proto-oncogene activity in other
cell types.
A recent report documented the presence of point mu-
tations in strategic sites within Notch-1 that ultimately pro-
duced a receptor that was more readily processed by g-
secretase, leading to a sustained Notch-1 receptor signa-
ling in approximately 50% of the cases of T cell acute
lymphoblastic leukemias (Weng et al, 2004). This makes it
the most frequently mutated oncogene in this disease
(Fig 2B). Earlier, a chromosomal translocation (t 7; 9) was
identified in a rare (  10%) subset of T-ALL patients that
also resulted in elevated Notch-1 receptor signaling (Re-
ynolds et al, 1987; Ellisen et al, 1991). Using a mouse mod-
el, forced overexpression of the truncated form of the
human Notch-1 gene in the hematopoietic compartment
also produced T cell leukemia (Pear et al, 1996). This con-
sisted of CD4þ , CD8þT-cells, and appeared after a laten-
cy period, suggesting that other mutations are required.
Besides T-ALL, there are many other examples of deregu-
lated expression of wild-type Notch receptors in human
tumors including: head and neck carcinomas, renal carci-
nomas, endometrial carcinomas, mesothelioma, breast,
lung, and pancreatic carcinomas, as well as chronic lymph-
oid and a subset of acute myeloid leukemias, anaplastic
large cell non-Hodgkin lymphomas, and a subtype of Hodg-
kin lymphoma (Nickoloff et al, 2003). As regards interactions
between Notch and other oncogenic pathways of relevance
to investigative skin biologists, it should be noted that
cross-talk involving the Wnt signaling pathway as well as
the Sonic-Hedgehog pathway has been observed (Thelu
et al, 2002). Both Wnt- and Hedgehog-mediated signaling
are of increasing interest to investigators studying carcin-
ogenesis-related pathways (Beachy et al, 2004). In the next
section, a brief review of the mechanism by which Ras and
Notch signaling can influence the neoplastic phenotype in
melanoma will be presented.
Ras and Notch Signaling in Melanoma
Prior to the discovery of the aforementioned activating point
mutations in Notch-1 found in T-ALL patients, several lab-
oratories had focused on the interaction between Ras
signaling and the Notch pathway (Fig 3). It was discovered
that oncogenic Ras could enhance Notch signaling by at
least two distinct, but complementary, pathways (Weijzen
et al, 2002). The first way in which oncogenic Ras can en-
hance Notch signaling is by increasing the level of Notch
ligands such as Delta-1, and the second mechanism is
by increasing the levels of the g-secretase/presenilin 1
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complex (Nickoloff et al, 2003). We are focusing on Ras in
this review because of the importance of Ras signaling in
the pathogenesis of melanoma (Herlyn et al, 2002). It also
appears that Ras-mediated transformation requires the
presence of intact Notch signaling, and if such Notch re-
ceptor signaling is disrupted, the ability of Ras to transform
cells is significantly reduced (Weijzen et al, 2002; Kiaris et al,
2004). Although the precise mechanistic details by which
Notch signaling can contribute to tumorigenesis remain to
be defined, several interesting insights have been gained by
focusing on cell survival pathways. It appears that Notch
signaling can enhance the survival of cells by interacting
with the PKB/AKT (Rangarajan et al, 2001a), as well as NF-
kB pathways (Cheng et al, 2001).
The molecular and genetic pathways contributing to the
transformation of normal melanocytes to melanomas are
the subject of intense investigation (Herlyn et al, 2002). One
important reason for this interest is that the incidence of
melanoma is rapidly increasing, as is the mortality from this
deadly neoplasm (Buzzell and Zitelli, 1996; Houghton and
Polsky, 2002). Figure 4 provides a representative phase-
contrast microscopic appearance of normal proliferating
human melanocytes, as well as a panel of ten different me-
lanoma cell lines. This collection of melanoma cells includes
early-passage (o50 passages; RJ002L, BO-003) as well as
many late-passage cells (450 passages; C8161, MUM2B,
MUM2C, C81-61, OCM1A, SK-Mel 5, SK-Mel 100, and SK-
Mel 147). Note that normal melanocytes have elongated
cytoplasmic processes resembling neuronal dendrites,
whereas the melanoma cell lines appear either epithelioid
or spindle shaped and display a tendency to pile up as they
proliferate. As can be appreciated by the differences in the
appearance of the cultured cells, morphology does not pre-
dict Notch expression as detailed in Figs 4 and 5. CEM cells
grow in suspension and are also portrayed in Fig 4 as they
represent a cell line with markedly enhanced Notch-1 levels
as mentioned earlier for T-ALL cells (Weng et al, 2004).
Abnormalities involving several important proteins have
been uncovered in the pathogenesis of melanoma includ-
ing: inactivation of p16INK4a, cyclin-dependent kinase inhib-
itor (CDK4/6) with suppression of Rb protein, silencing of
the pro-apoptotic protein APAF-1, activating mutations in B-
Raf and N-Ras, and constitutive activation of mitogenic re-
ceptor signaling pathways including basic fibroblast growth
factor receptor (Reed et al, 1995; Buzzell and Zitelli, 1996;
Dracopoli and Fountain, 1996; Davies et al, 2002; Alsina
et al, 2003; Soengas and Lowe, 2003; Tucker and Goldstein,
2003). There may also be deregulation of E2F transcriptional
activity, as well as alterations in the Wnt pathway involving
Wnt5a (Halaban et al, 2000; Weeraratna et al, 2002). Two of
the most common molecular lesions in melanomas, namely,
activation of Ras signaling and inactivation of the G1
checkpoint, can potentially result in enhanced Notch signa-
ling (Ras) and co-operate with the transforming activity of
Notch-1. As discussed earlier, whereas there are multiple
Notch receptors and ligands, due to space constraints, this
review will focus predominantly on Notch-1 receptor acti-
vation in melanoma as a paradigm for understanding the
role of Notch signaling in carcinogenesis.
Since melanocytes arise from the neural crest, and be-
cause Wnt as well as Notch developmental signaling cas-
cades regulate central nervous system stem cell dynamics,
it was possible that Notch signaling may be activated in
melanoma cells, as well as in various neural crest-derived
brain tumors (Fan et al, 2004). In melanocytes and me-
lanoma cells, one of the first steps in determining whether
Notch signaling may have been relevant in the pathogenesis
of melanoma is to assess the relative levels and state of
activation for Notch receptors in both melanocytes as well
as melanoma cells (Fig 5). In two earlier reports, we initially
used an immunohistochemical staining approach, and al-
though we could not detect any of the four different Notch
receptors to be expressed by melanocytes in normal or
diseased skin, enhanced immunoreactivity was detected for
all four different Notch receptors in melanoma lesions (Hen-
drix et al, 2002; Nickoloff et al, 2003). Interest in Notch
signaling in melanoma derived from the observation that
some aggressive melanoma cell lines displayed a stem
cell-like plasticity, and the question as to a role for Notch
Figure 3
Role of cross-talk between oncogenic Ras and Notch receptors in
melanoma, and portrayal of therapeutic targets derived from this
signaling pathway. Note that there are at least two mechanisms by
which activated Ras can enhance Notch signaling: either by inducing
Notch ligand expression, or by enhancing g-secretase activity. Tran-
scriptional targets for Notch signaling in tumor cells include Hes-1,
STAT3, NF-kB, and p21. Therapeutic approaches for interrupting Notch
signaling include use of GSI (g-secretase inhibitor), or a genetic silenc-
ing approach featuring RNAi targeting individual Notch receptors (see
text for further explanation).
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signaling as an underlying molecular mechanism for the
trans-differentiation between melanoma cells and end-
othelial cells arose from such studies (Hendrix et al, 2004).
Given the role of Notch signaling in regulating vasculature
formation during embryogenesis (Gridley, 2001; Uytten-
daele et al, 2001), the enhanced levels of Notch receptors in
melanoma were consistent with this developmental-related
theme for melanoma pathogenesis. To extend our immuno-
staining results, a polyclonal rabbit-derived antibody de-
tecting the activated state of Notch-1 (Abcam, Cambridge,
Massachusetts) was used to probe whole-cell extracts. No
activated Notch-1 was detected by western blot analysis in
any of the proliferating normal human melanocytes derived
from ten different foreskins (Fig 5). Using ten different me-
lanoma cell lines, however, activated Notch-1 was detected
in all of the cell lines, albeit at variable levels of overex-
pression and irrespective of their morphology (spindle
shaped or epithelioid) as shown in Fig 4. The T-ALL cell
line, CEM, was used as a positive control as it contains
abundant activated Notch-1. As regards the overexpression
of Notch receptors that we have detected in human me-
lanomas, another group using a microarray approach has
also independently verified enhanced Notch mRNA levels in
melanoma (Hoek et al, 2004), and our recently completed
real-time quantitative polymerase chain reaction analysis of
these ten melanoma cell lines confirmed elevated levels for
all four Notch receptor mRNAs compared with normal pro-
liferating melanocytes.1
Concept of Synthetic Lethality
As one considers the biology of oncogenic events, it is im-
portant to note that, in general, most cancer-associated
growth-promoting signals are directly coupled to increased
cell death (Hanahan and Weinberg, 2000). Thus, initial onc-
ogenic events can only have a net tumor growth effect when
they are complemented by, or cooperate with, anti-apopto-
tic pathways in tumor cells. Identification of this specific
apoptotic vulnerability in melanoma can then be targeted to
achieve selective killing of malignant cells while sparing
non-transformed (i.e., normal) cells (Hartwell et al, 1997).
This approach has been termed synthetic lethality because
it emphasizes combining a drug that does not affect normal
cells that contain wild-type alleles, with induction of death in
malignant cells containing a specific genetic alteration that
renders the tumor cell susceptible to induction of apoptosis
(Reddy and Kaelin Jr, 2002). Figure 6 provides an overview
of these concepts including the pharmacogenomic strategy
as applied to synthetic lethality in melanoma. The term
‘‘pharmacogenomic’’ is used here not to indicate the study
of inter-individual genetic variability in drug susceptibility,
but to indicate the genetic basis for differential drug sus-
ceptibility between normal cells and cancer cells.
As portrayed in Fig 6, a normal cell is depicted with a
properly balanced set of proteins regulating proliferation
and apoptosis, but following proto-oncogene activation
(e.g., c-myc activation), there is enhancement in both pro-
liferation and apoptosis such that no net tumor is formed.
Following an additional genetic alteration such as increased
Bcl-xL, NF-kB, or AKT, the enhanced survival pathway
Figure 4
Phase-contrast microscopic appearance of proliferating human melanocytes derived from normal skin, and a panel of melanoma cell lines
derived from patients with metastatic melanoma. (Magnification  85) (A) Normal human melanocytes. (B–K) Melanoma cell lines. (L) T-ALL cell
line: CEM cells. Note that normal human melanocytes were derived from neonatal foreskins and grown in standard medium (Qin et al, 2004).
Melanoma cell lines and CEM cells were grown in RPMIþ10% FCS. All cells were maintained at 371C in a humidified incubator with 5% CO2.
1B. J. Nickoloff, A. Weeraratna, unpublished observations,
2004.
100 NICKOLOFF ET AL JID SYMPOSIUM PROCEEDINGS
overcomes the pro-apoptotic tendency to shift the balance
in favor of tumor formation. There are several examples in
which an oncogenic genetic alteration can sensitize the
tumor cells to induction of apoptosis including: activation
and deregulation of MYC that leads to either sustained E2F-
1 levels that trigger caspase activation and apoptosis, or
enhanced death receptor (DR5)-mediated susceptibility
(Wang et al, 2004). Another relevant example is the activa-
tion of Ras/Src that is accompanied by sensitization to lys-
osomal cysteine protease, cathepsin B (Fehrenbacher et al,
2004). By using agents that can exploit the hypersensitivity
of malignant cells, a pharmacogenomics approach that is
analogous to the concept of genetic synthetic lethality can
be envisioned for a molecularly targeted therapeutic appli-
cation. In this review, data are presented indicating that
Notch receptor activation is abnormal in melanoma cells,
and in the next section focus is directed toward the use of
an agent initially selected to block Notch signaling. This line
of inquiry led to the discovery of a novel apoptotic pathway
featuring induction of a BH3-only pro-apoptotic protein
known as NOXA.
Use of gamma-secretase inhibitor (GSI) to
Induce NOXA in Melanoma Cells
Since all four different Notch receptors appear to be acti-
vated in melanoma lesions (Nickoloff et al, 2003), we de-
cided to use a GSI that could simultaneously inhibit all
Notch receptor pathways (Weijzen et al, 2003). GSI is a
tripeptide aldehyde that resembles other agents developed
for the treatment of Alzheimer’s disease (Wolfe, 2001). The
chemical structure of GSI is depicted in Fig 6. Since the b-
amyloid peptide in senile plaques requires a cleavage step
similar to Notch receptor processing, many such inhibitors
are already available, and some are in clinical trials that will
provide valuable patient tolerability and safety data for fu-
ture drug development in melanoma patients (Josien, 2002).
According to a published report (Qin et al, 2004), when
proliferating melanocytes or melanoma cells were exposed
to GSI, the melanocytes underwent a G2/M growth arrest,
but the melanoma cells underwent rapid and prominent
apoptosis, as summarized in the bottom portion of Fig 6.
Next, studies were designed to define the mechanism of
action for the selective apoptotic response of GSI in me-
lanoma cells (Qin et al, 2004). To identify the apoptotic
pathway, both melanocytes and melanoma cells were stud-
ied, and the kinetics of induction of apoptosis following ad-
dition of GSI to melanoma cells was determined. Using a
panel of five different melanoma cell lines, including an ear-
ly-passage metastatic melanoma cell line (RJ002L) or four
different late-passage melanoma cell lines (C8161, MUM2B,
SK-Mel-28, SK-Mel-100), the induction of apoptosis be-
came detectable by Annexin V-FITC staining and flow
cytometry approximately 6–8 h after exposure to GSI. To
determine whether this apoptosis required new protein syn-
thesis of pro-apoptotic factor(s), or could be attributed to
the loss of survival factor(s), melanoma cells were pre-
treated with cycloheximide (1 mg per mL; 1 h) to block pro-
tein synthesis, and then exposed to GSI. The inhibition of
new protein synthesis almost completely blocked the GSI-
mediated induction of apoptosis. This result strongly point-
ed toward induction of a pro-apoptotic signal following GSI,
so whole-cell extracts were prepared before and at various
time intervals (1, 3, 6, 18, 24 h) following GSI exposure.
Western blots were probed for numerous survival and apo-
ptotic proteins, and it was discovered that the most rapid
(approximately 3 h) and prominent pro-apoptotic protein
induced by GSI was the BH3-only protein, NOXA. Another
BH3-only protein, Bim, was also induced but at later time
points (18, 24 h). Western blots for the melanoma cells re-
vealed constitutive levels of the important apoptotic pro-
teins Bax and Bak, as well as high levels for survival
proteins Bcl-2, Mcl-1, and survivin.
One reason why it took such a long time to discover the
basis for induction of NOXA was previous reports implying
that p53 was necessary for NOXA induction (Qin et al,
2004). Since several of the melanoma cell lines contained
mutations in both p53 alleles, the initial survey of candidate
proteins did not include p53-inducible proteins such as
NOXA. But, once the rapid and prominent induction of
NOXA was detected using two different antibodies that
correctly detected a single protein of the correct molecular
mass, we next asked four important questions. First, was
GSI-induced NOXA p53 dependent? Second, did GSI in-
duce NOXA in normal melanocytes? Third, did other agents
used to treat melanoma or other cancers induce NOXA?
Fourth, did blocking NOXA induction reduce the apoptotic
response in melanoma cells? To determine whether p53
was required for NOXA induction, we initially reduced
p53 levels using an siRNA approach and while inhibiting
Figure 5
Status of Notch-1 receptor levels and activation in normal human
melanocytes and melanocytes and melanoma cell lines. Western
blot analysis of ten different normal human melanocyte cultures and ten
different human melanoma cell lines examined for activated Notch-1
receptors (acute T cell lymphoblastic leukemia line; CEM cells contain-
ing activating point mutations in Notch-1 as a positive control). Des-
ignation of normal melanocytes represents ten different neonatal
foreskins, as follows: lane 1, MC-07; lane 2, MC-08; lane 3, MC-06;
lane 4, MC-04; lane 5, MC-05; lane 6, MC-010; lane 7, MC-011; lane 8,
MC-012, lane 9, MC-013; and lane 10, MC-014. Lane numbers des-
ignated for the melanoma cell lines are as follows: lane 1, C8161; lane
2, MUM2B; lane 3, RJ-002L; lane 4, BO-003; lane 5, MUM2C; lane 6,
C81-61; lane 7, OCM1A; lane 8, SK-Mel 5, lane 9, SK-Mel 100; and lane
10, SK-Mel 147. Whole-cell extracts (50 mg protein per lane) were pre-
pared as previously described (Qin et al, 2004), and western blotting
was performed using: anti-Notch-1 (Abcam ab8925), anti-actin (Santa
Cruz Biotechnology, Santa Cruz, California) antibodies.
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GSI-induced levels of two p53-dependent proteins (GAD-
D45, MDM2), no reduction in GSI-induced NOXA was ob-
served. Next, we used two other cell lines known to be p53
null (e.g., PC-3 prostate cancer cells, SAOS-2 osteogenic
sarcoma cells), as well as verified that two of our melanoma
cell lines (MUM2B, SK-Mel-28) were p53 null, and observed
that whereas no p53 protein was detected, GSI could still
induce NOXA and trigger cell death. When normal prolifer-
ating melanocytes were treated with GSI, no NOXA was
induced, although the cells underwent a prominent G2/M
growth arrest. Treatment of melanoma cells with genotoxic
agents such as adriamycin (1 mg per mL), etoposide (10 mg
per mL), or UV light (30 mJ per cm2), induced a slight apo-
ptotic response, but no expression of NOXA. Finally, when
an antisense oligonucleotide targeting NOXA was used to
prevent NOXA induction, the apoptotic response to GSI was
reduced by approximately 30%–50% depending on the cell
line utilized. Taken together, these results strongly support-
ed the conclusion that GSI was inducing apoptosis in me-
lanoma cell lines by engaging a previously uncharacterized
apoptotic pathway that was, in part, dependent on the BH3-
only protein, NOXA. Importantly, GSI caused striking cell
death and NOXA induction in melanoma xenografts as well,
without causing observable toxicity to nude mice. This sug-
gests that it may be possible to identify a therapeutic win-
dow for use of GSI in melanoma.
The final aspect of this study was to further delineate the
sequence of molecular events occurring in the melanoma
cells once NOXA was induced. As NOXA is a BH3-only
protein, it can bind the pro-survival proteins Mcl-1, Bcl-2,
and Bcl-x, thus facilitating interaction between the pro-
apoptotic proteins Bax and Bak located in the mitochondrial
membrane (Fig 7). Evidence for this interaction leading to
mitochondrial dysfunction included release of cytochrome
C from the mitochondria into the cytoplasm. Once cyto-
chrome C is released, it can facilitate creation of the apo-
ptotic complex in which APAF-1 is recruited, leading to
caspase 9 activation, followed by activation of caspase 3,
cleavage of PARP and other ‘‘end-stage’’ substrates, and
culminating in DNA degradation and cell death. Interesting-
ly, whereas APAF-1 levels were barely detectable in several
melanoma cell lines, and the cells had high levels of anti-
apoptotic factors (e.g. Bcl-2, Mcl-1, survivin), the induction
of NOXA was sufficient to overcome all of these obstacles
to trigger a prominent apoptotic response in all of the me-
lanoma cell lines irrespective of their p53 status.
Further studies are required to more fully determine
whether other stimuli (besides GSI) can trigger NOXA in-
duction in a p53-independent fashion in melanoma cells,
and to elucidate the mechanism responsible for the inability
of GSI to induce NOXA in normal melanocytes. It will also
be necessary to determine whether GSI induction of NOXA
Figure 6
Overview of pharmacogenomic strategy for synthetic lethality including use of gamma-secretase inhibitor (GSI) to achieve selective killing
of melanoma cells, but not normal melanocytes. The initial proto-oncogenic activation (portrayed by c-myc) within a normal cell (green highlights)
induces both enhanced proliferation that is offset by enhanced apoptosis (portrayed by increased death receptor-DR5 levels) yielding no net tumor
formation (yellow highlights). When additional genetic alterations are present (portrayed by increased Bcl-x, NF-kB, or AKT), the balance between
proliferation and apoptosis is tipped toward enhanced survival pathways leading to tumor formation (red highlights). An ideal selective chemo-
therapeutic agent such as GSI (N-benzyloxycarboxy Leu-Leu-Nle-CHO) can trigger growth arrest, but not apoptosis in normal melanocytes,
whereas GSI induces prominent killing of melanoma cell lines (Qin et al, 2004). An important molecular determinant for selective killing of melanoma
cells versus melanocytes is the ability of GSI to induce the proapoptotic BH3-only protein NOXA in melanoma cells, but not in normal melanocytes.
One potentially important characteristic of melanoma cells is their activation of Notch receptors relative to melanocytes, although the specific link
between Notch signaling and GSI-mediated induction of NOXA remains to be defined. This figure is derived from several publications including
Hanahan and Weinberg (2000), Hartwell et al (1997) and Wang et al (2004).
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results from inhibition of Notch signaling alone, given that
g-secretase has numerous substrates, including: ErbB4,
syndecan, CD44, and others (Qin et al, 2004).
Conclusions
Taken together, these results indicate that Notch receptor
activation is a characteristic of melanoma cells, which dis-
tinguishes the malignant cells from normal melanocytes.
Moreover, by using an agent that was initially chosen to
target the activation of all Notch receptors, selective
apoptosis of melanoma cells could be achieved while spar-
ing normal melanocytes. The selective killing of melanoma
cells was attributed, in part, to induction of NOXA, as GSI
triggered the pro-apoptotic BH3-only protein NOXA exclu-
sively in melanoma cells and not melanocytes. Moreover,
the use of an antisense oligonucleotide targeting NOXA
significantly reduced the GSI-induced apoptosis in me-
lanoma cells.
Future studies are indicated to determine the precise
mechanism whereby Notch receptor-mediated signaling
pathways provide a survival advantage to melanoma cells.
It will be important to elucidate the relationship between re-
duction in Notch signaling, and engagement of the apopto-
tic machinery in melanoma cells. Finally, devising additional
reagents that can selectively target NOXA induction in me-
lanoma cells, while sparing normal melanocytes, will pro-
vide new therapeutic options for patients with melanoma.
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